EP
MRNA icon

Elkhorn Partners’s Moderna MRNA Stock Holding History

Elkhorn Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,500
Closed -$104K – 42
2024
Q4 		$104K Buy
2,500
+300
+14% +$14.3K 0.07% 28
2024
Q3 		$147K Buy
+2,200
New +$202K 0.09% 22
2024
Q1 		– Sell
-550
Closed -$55K – 49
2023
Q4 		$55K Sell
550
-630
-53% -$53K 0.04% 38
2023
Q3 		$122K Buy
1,180
+880
+293% +$98.2K 0.08% 28
2023
Q2 		$36K Buy
+300
New +$40K 0.02% 43
2021
Q2 		– Sell
-300
Closed -$39K – 51
2021
Q1 		$39K Buy
+300
New +$43.5K 0.02% 33

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Elkhorn Partners's MRNA Position: Q1 2025 in Review

Elkhorn Partners sold out of Moderna (MRNA) in Q1 2025, closing a stake of 2,500 shares — an estimated $104K sold.

Elkhorn Partners first reported a position in MRNA in Q1 2021 and held it in 6 quarters. The position peaked at $147K in Q3 2024. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Elkhorn Partners reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Elkhorn Partners sold 2,500 Moderna shares in Q1 2025, an estimated $104K.
  • Elkhorn Partners first reported a position in Moderna in Q1 2021 and held it in 6 quarters.
  • Elkhorn Partners's Moderna position peaked at $147K in Q3 2024.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Elkhorn Partners's 13F filing for Q1 2025, filed 14 May 2025.